South Africa has taken a monumental step in its fight against HIV with the registration of a long-acting prevention injection. The South African Health Products Regulatory Authority (SAHPRA) has announced the approval of the antiretroviral drug lenacapavir. Global health experts have hailed the twice-yearly jab as a “game-changer.” The prestigious journal Science named the injection, which provides six months of…
Tag: Pharmaceutical
-
Cipla Medpro faces claims over side effects of antibiotic
Cipla Medpro faces claims that it failed to adequately warn patients about the potentially severe side effects of a common antibiotic. These claims arose after a Johannesburg man suffered four life-altering tendon ruptures. A man in his 40s is now considering legal action against the company. He was prescribed Tavaloxx, a fluoroquinolone antibiotic, and alleges the warnings provided inside the…
-
Twice-Yearly HIV Jab: Activists Call for Lower Prices
A groundbreaking, twice-yearly injection for HIV prevention is hailed as a potential ‘game-changer’. However, it is at the centre of a fierce debate regarding affordability. Health activists worldwide implore its manufacturer, Gilead Sciences, to prevent a “missed opportunity for achieving equity.” This twice-yearly HIV jab could revolutionise prevention efforts. But that will only occur if it becomes accessible to all.…
-
HIV Prevention Strategies with Lenacapavir Injection
In a decision that could fundamentally reshape the fight against HIV, the US Food and Drug Administration (FDA) has given its approval to Gilead Sciences’ lenacapavir, a groundbreaking twice-yearly injection for preventing HIV infection in adults and adolescents. Marketed under the brand name Yeztugo in the US, this innovative drug has been eagerly anticipated by both investors and HIV/AIDS activists…
-
Adcock Ingram: A picture of resilience in a challenging market
Pharmaceutical stalwart Adcock Ingram presents a compelling case for investors seeking resilience amidst potential market turbulence. The group boasts a robust track record, with a mere 3% dip in headline earnings per share (HEPS) during the challenging Covid-impacted year of 2021. It was their worst annual performance in a decade. Since 2015, Adcock has delivered an impressive 16.2% compound annual…